At a Glance
Therapeutic Area:
Approved Applications:
Metastatic castration-resistant prostate cancer (CRPC)

Xtandi™ (enzalutamide) is a leading treatment for men with metastatic castration-resistant prostate cancer (CRPC). Initially approved by the FDA in August 2012 and by the EMA in August 2013 for metastatic CRPC patients who were previously treated with chemotherapy, the approval was later expanded to all patients with metastatic CRPC regardless of whether they received prior chemotherapy.
Applications In Development:
Non-metastatic CRPC; hormone sensitive non-metastatic prostate cancer
Acquisition Date:
March 2016
Royalty Seller:




xtandi logo
© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.